Biotech firm awarded £880k to develop digital cancer testing platform

A Manchester business which has developed a digital screening platform that enables the rapid diagnosis of cancer has been awarded an £880,000 NHS development contract to bring the technology to market. Chromition, a University of Manchester spin-out which is backed by Mercia Fund Managers, has developed light-emitting particles known as luminspheres which can be attached to biomarkers that bind to cancer cells and give off light to indicate the presence of cancer. Tissue samples can be screened using existing equipment and the... For the full story register now for free or login below...
Close